La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Orexo Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Orexo ha un patrimonio netto totale di SEK24.2M e un debito totale di SEK458.5M, che porta il suo rapporto debito/patrimonio netto a 1894.6%. Le sue attività totali e le sue passività totali sono rispettivamente SEK773.3M e SEK749.1M. L'EBIT di Orexo è SEK6.9M rendendo il suo rapporto di copertura degli interessi 0.2. Ha liquidità e investimenti a breve termine pari a SEK139.7M.

Informazioni chiave

1,894.6%

Rapporto debito/patrimonio netto

SEK 458.50m

Debito

Indice di copertura degli interessi	0.2x
Contanti	SEK 139.70m
Patrimonio netto	SEK 24.20m
Totale passività	SEK 749.10m
Totale attività	SEK 773.30m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%

Aug 02

Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price

Jul 20

Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward

May 29

Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry

Apr 03

We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt

Dec 09

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Jun 14

Is Orexo (STO:ORX) A Risky Investment?

Apr 27

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Oct 19

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Sep 09

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

May 26

Is Orexo (STO:ORX) Using Too Much Debt?

Apr 16

Orexo (STO:ORX) Has Debt But No Earnings; Should You Worry?

May 04

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( SEK466.4M ) di ORX superano le sue passività a breve termine ( SEK263.6M ).

Passività a lungo termine: Le attività a breve termine di ORX ( SEK466.4M ) non coprono le sue passività a lungo termine ( SEK485.5M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 1317.4% ) di ORX è considerato alto.

Riduzione del debito: Il rapporto debito/patrimonio netto di ORX è aumentato da 58.1% a 1894.6% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: ORX ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: Dati insufficienti per determinare se ORX ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.

Orexo Salute del bilancio

Salute finanziaria criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt

Is Orexo (STO:ORX) A Risky Investment?

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Is Orexo (STO:ORX) Using Too Much Debt?

Orexo (STO:ORX) Has Debt But No Earnings; Should You Worry?

Recent updates

Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%

Consensus EPS estimates fall by 45%

Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price

Price target decreased by 10% to kr21.50

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Orexo AB (publ) to Report Q1, 2025 Results on May 06, 2025

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr70k worth of stock

Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward

Orexo AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Consensus EPS estimates upgraded to kr1.95 loss

First quarter 2024 earnings released: kr0.26 loss per share (vs kr1.86 loss in 1Q 2023)

Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US

Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 127%

Orexo AB (Publ) Announces Board Resignations

President & CEO recently bought kr148k worth of stock

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Independent Chairman of the Board recently bought kr361k worth of stock

No longer forecast to breakeven

Executive VP & CFO recently bought kr81k worth of stock

Third quarter 2023 earnings: Revenues exceed analyst expectations

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (publ) Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) to Report Q2, 2024 Results on Jul 17, 2024

Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio

President & CEO recently bought kr74k worth of stock

Second quarter 2023 earnings: Revenues exceed analyst expectations

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target decreased by 15% to kr31.00

First quarter 2023 earnings: Revenues exceed analyst expectations

Is Orexo (STO:ORX) A Risky Investment?

President & CEO recently bought kr189k worth of stock

Orexo AB (publ) Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose

Full year 2022 earnings released: kr5.17 loss per share (vs kr6.51 loss in FY 2021)

Orexo AB (publ.) Initiates Exploratory Feasibility Studies of amorphOX with Two Leading Biopharmaceutical and Vaccine Companies

Orexo AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Consensus forecasts updated

Third quarter 2022 earnings released

Orexo AB (publ) Announces Last Patient Enrolled in Pivotal Study Evaluating the Efficacy of MODIA® in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Orexo Announces Positive Data from Phase 1 Clinical Study for OX640

Orexo AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Consensus forecasts updated

Independent Director recently bought kr60k worth of stock

Second quarter 2022 earnings released

Orexo AB (Publ.) Announces Successfully Initiated the First Explorative Human Clinical Study for Ox640

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

Consensus estimates of losses per share improve by 22%

First quarter 2022 earnings: Revenues in line with analyst expectations

Price target decreased to kr28.00

Orexo AB (publ) Announces Board Appointments

Is Orexo (STO:ORX) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations

Director recently bought kr505k worth of stock

Consensus forecasts updated

Price target decreased to kr54.00